Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2015

Open Access 01-12-2015 | Poster presentation

P025. Two-year follow-up with OnabotulinumtoxinA for chronic migraine: a real life evaluation of 113 patients

Authors: Antonio Santoro, Matteo Tanzi, Anna Miscio, Massimiliano Copetti, Maurizio Leone

Published in: The Journal of Headache and Pain | Special Issue 1/2015

Login to get access

Excerpt

OnabotulinumtoxinA (Botox®, Allergan) has shown its efficacy in chronic migraine (CM) in two phase III studies and up to 5 injection cycles [1]. However, few studies have been published based on its real life efficacy and few data are available on its efficacy beyond the 5th cycle of treatment [2]. …
Literature
1.
Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, et al: OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program. Headache. 2011, 51 (9): 1358-1373. 10.1111/j.1526-4610.2011.01990.x.CrossRefPubMed
2.
Cernuda-Morollón E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J: Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?. Cephalalgia. 2014, 35 (10): 864-868.CrossRefPubMed
Metadata
Title
P025. Two-year follow-up with OnabotulinumtoxinA for chronic migraine: a real life evaluation of 113 patients
Authors
Antonio Santoro
Matteo Tanzi
Anna Miscio
Massimiliano Copetti
Maurizio Leone
Publication date
01-12-2015
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue Special Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/1129-2377-16-S1-A182

Other articles of this Special Issue 1/2015

The Journal of Headache and Pain 1/2015 Go to the issue

Invited speaker presentation

Molecular genotype in migraine

Oral presentation

O052. Migraine without aura and osteopathic medicine, a non-pharmacological approach to pain and quality of life: open pilot study

Oral presentation

O036. Cocaine and headache: a 2-year follow-up study in chronic cocaine users and literature review

Poster presentation

P028. Childhood migraine, epilepsy and tics: Are there similarities in the psychological profile?

Oral presentation

O048. Chronic migraine, cluster headache or both? The suggestion of botulinum toxin

Invited speaker presentation

Vestibular migraine